Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors
Trial · NCT00940498
Adverse events2,472
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,472
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 10 mg | 0 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 21 mg | 1 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 43 mg | 1 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 89 mg | 1 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1 and 2: PF-05212384 154 mg | 6 | 42 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 222 mg | 1 | 7 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 266 mg | 2 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 319 mg | 2 | 4 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 10 mg | 0 | 4 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 21 mg | 0 | 4 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 43 mg | 0 | 4 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 89 mg | 0 | 4 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1 and 2: PF-05212384 154 mg | 1 | 42 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 222 mg | 0 | 7 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 266 mg | 0 | 8 | |
| other | Hypochromic anaemia | Blood and lymphatic system disorders | Part 1: PF-05212384 319 mg | 0 | 4 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: PF-05212384 10 mg | 0 | 4 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: PF-05212384 21 mg | 0 | 4 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: PF-05212384 43 mg | 0 | 4 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Part 1: PF-05212384 89 mg | 0 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00940498/events